OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urologic Neoplasms
Conditions
Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
Trial Timeline
Oct 1, 2011 → Nov 1, 2014
NCT ID
NCT01454089About OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin
OGX-427 600 mg + OGX-427 1000 mg + Placebo + Gemcitabine + Cisplatin + Carboplatin is a phase 2 stage product being developed by Achieve Life Sciences for Urologic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01454089. Target conditions include Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms.
What happened to similar drugs?
0 of 1 similar drugs in Urologic Neoplasms were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01454089 | Phase 2 | Completed |
Competing Products
16 competing products in Urologic Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 32 |
| Mirabegron + Solifenacin succinate + Placebo | Astellas Pharma | Phase 2 | 35 |
| Mirabegron + Solifenacin succinate | Astellas Pharma | Phase 3 | 40 |
| Gemcitabine | Eli Lilly | Phase 2 | 35 |
| pemetrexed | Eli Lilly | Phase 2 | 35 |
| ALIMTA + gemcitabine | Eli Lilly | Phase 2 | 35 |
| BBI503 | Sumitomo Pharma | Phase 2 | 27 |
| Pembrolizumab Injection [Keytruda] | Merck | Phase 2 | 42 |
| Carboplatin/Paclitaxel + Pembrolizumab | Merck | Phase 2 | 42 |
| zoledronic acid | Novartis | Phase 2 | 27 |
| mycophenolate mofetil | Roche | Phase 1 | 29 |
| Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 35 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 42 |
| CBT101 + Placebo | Brain Biotech | Phase 1 | 26 |
| S-8184 Paclitaxel Injectable Emulsion + Experimental Arm: TOCOSOL Paclitaxel | Achieve Life Sciences | Phase 2 | 25 |
| Stem Cell | Brain Biotech | Phase 1 | 11 |